1280204-67-2Relevant academic research and scientific papers
Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy
Martínez González, Sonia,Rodríguez-Arístegui, Sonsoles,Hernández, Ana Isabel,Varela, Carmen,González Cantalapiedra, Esther,álvarez, Rosa María,Rodríguez Hergueta, Antonio,Bischoff, James R.,Albarrán, María Isabel,Cebriá, Antonio,Cendón, Elena,Cebrián, David,Alfonso, Patricia,Pastor, Joaquín
, p. 2536 - 2543 (2017/05/10)
The involvement of the phosphoinositide 3-kinases (PI3Ks) in several diseases, especially in the oncology area, has singled it as one of the most explored therapeutic targets in the last two decades. Many different inhibitor classes have been developed by
FUSED IMIDAZO [3, 2 - D] PYRAZINES AS PI3 KINASE INHIBITORS
-
Page/Page column 103; 134, (2011/04/24)
There is provided compounds of formula (I), wherein A1, A2, A3, A4, n, the dotted lines, B1, B1a, B2, B2a, B3, B3a, B4, B4a, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
